CSF3 and type 1 diabetes mellitus: The Type 1 Diabetes TrialNet Study Group performed a three-arm, randomized, double-masked, placebo-controlled trial in which the primary outpoint was to evaluate the area under the curve (AUC) of C-peptide by comparing ATG and ATG + G-CSF treatments.